Instem (INS)

Executive Summary

Instem is a UK-based provider of SaaS software solutions for the global life sciences R&D sector, with a history dating back to 1970. The company offers a comprehensive suite of platforms focused on in silico modeling, data insights, study management, regulatory submission, and clinical trial analytics. Its software is designed to help pharmaceutical, biotech, CRO, and academic clients accelerate research, ensure regulatory compliance, and drive data-driven decision-making. Instem is privately held and listed on the AIM market under ticker INS, serving a niche but critical segment of the drug development value chain. Instem's competitive advantage lies in its integrated, end-to-end platform that covers the full R&D lifecycle, from preclinical discovery through regulatory submission and clinical trials. With increasing adoption of AI/ML in drug development and growing regulatory complexity, Instem is well-positioned to capture market share. However, the company faces competition from larger players and must continuously innovate to maintain its edge. Given its established customer base and recurring SaaS revenue model, Instem offers a relatively stable investment opportunity within the life sciences technology space.

Upcoming Catalysts (preview)

• Q2 2026Launch of AI-enhanced clinical trial analytics module70% success
• H2 2026Major partnership with top 10 pharmaceutical company for regulatory submission software60% success
• Q3 2026Filing of new patent for in silico prediction technology80% success